

PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	OMIM	Books
Search PubMed	▼ for						Go	Clear
Limits		Preview/Index		History		Clipboard		Details

Display	Abstract	▼	Show: 20	▼	Sort	▼	Send to	Text	▼
---------	----------	---	----------	---	------	---	---------	------	---

☐ 1: Biochemistry. 1995 Oct 17;34(41):13390-7.

[Related Articles, Links](#)

Entrez
PubMed

A peptide from the heptad repeat of human immunodeficiency virus gp41 shows both membrane binding and coiled-coil formation.

Rabenstein M, Shin YK.

PubMed
Services

Department of Chemistry, University of California, Berkeley 94720, USA.

Related
Resources

The envelope glycoprotein gp41 from human immunodeficiency virus type 1 (HIV-1) is involved in membrane fusion and virus entry. It contains a functionally important leucine zipper-like heptad repeat region (residues 553-590). To investigate the solution structure and membrane-binding properties of this region, cysteine-substituted variants of a 38-residue peptide derived from the heptad repeat were synthesized and modified with nitroxide spin labels. Analytical equilibrium ultracentrifugation studies indicated it is primarily tetrameric in solution, in contrast to the protein gp160 which is a mixture of trimers and tetramers. Electron paramagnetic resonance (EPR) measurements indicated that the peptide was bound to vesicles containing 10 mol % negatively charged lipids. The peptides were bound parallel to the membrane surface, near the water-membrane interface, in a structure different from the solution structure, most likely as monomers. When Asp, Pro, or Ser was substituted for Ile at the core "a" position of the heptad repeat in the middle of the peptide, the coiled coil was destabilized. In addition, these peptides showed reduced membrane-binding affinities. Thus, mutations that destabilized coiled-coil formation also decreased membrane-binding propensity. These experimental results, taken with previous evidence, suggest two functions for the heptad repeat of gp41 after CD4 binding: (1) to form an extended coiled coil; (2) to provide a hydrophobic face that binds to the host-cell membrane, bringing the viral and cellular membranes closer and facilitating fusion.

PMID: 7577925 [PubMed - indexed for MEDLINE]

Display	Abstract	▼	Show: 20	▼	Sort	▼	Send to	Text	▼
---------	----------	---	----------	---	------	---	---------	------	---

[Write to the Help Desk](#)



PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	OMIM	Books	
Search	PubMed	<input type="checkbox"/> for						Go	Clear
Limits Preview/Index History Clipboard Details									
Display	Abstract	<input type="checkbox"/>	Show: 20	<input type="checkbox"/>	Sort	<input type="checkbox"/>	Send to	Text	<input type="checkbox"/>

☐ 1: Biochemistry. 1995 Oct 17;34(41):13390-7.

[Related Articles, Links](#)

Entrez
PubMed

A peptide from the heptad repeat of human immunodeficiency virus gp41 shows both membrane binding and coiled-coil formation.

Rabenstein M, Shin YK.

PubMed
Services

Department of Chemistry, University of California, Berkeley 94720, USA.

Related
Resources

The envelope glycoprotein gp41 from human immunodeficiency virus type 1 (HIV-1) is involved in membrane fusion and virus entry. It contains a functionally important leucine zipper-like heptad repeat region (residues 553-590). To investigate the solution structure and membrane-binding properties of this region, cysteine-substituted variants of a 38-residue peptide derived from the heptad repeat were synthesized and modified with nitroxide spin labels. Analytical equilibrium ultracentrifugation studies indicated it is primarily tetrameric in solution, in contrast to the protein gp160 which is a mixture of trimers and tetramers. Electron paramagnetic resonance (EPR) measurements indicated that the peptide was bound to vesicles containing 10 mol % negatively charged lipids. The peptides were bound parallel to the membrane surface, near the water-membrane interface, in a structure different from the solution structure, most likely as monomers. When Asp, Pro, or Ser was substituted for Ile at the core "a" position of the heptad repeat in the middle of the peptide, the coiled coil was destabilized. In addition, these peptides showed reduced membrane-binding affinities. Thus, mutations that destabilized coiled-coil formation also decreased membrane-binding propensity. These experimental results, taken with previous evidence, suggest two functions for the heptad repeat of gp41 after CD4 binding: (1) to form an extended coiled coil; (2) to provide a hydrophobic face that binds to the host-cell membrane, bringing the viral and cellular membranes closer and facilitating fusion.

PMID: 7577925 [PubMed - indexed for MEDLINE]

Display	Abstract	<input type="checkbox"/>	Show: 20	<input type="checkbox"/>	Sort	<input type="checkbox"/>	Send to	Text	<input type="checkbox"/>
---------	----------	--------------------------	----------	--------------------------	------	--------------------------	---------	------	--------------------------


[Write to the Help Desk](#)

Background & Purpose

Recent studies suggest that HIV-1 envelope (Env) is a trimer on the native virus particle. In addition, it has been proposed that trimeric HIV-1 envelope vaccines may elicit better neutralizing antibodies because they more closely mimic the native HIV-1 envelope. Two soluble, trimeric HIV-1 Env2 envelope vaccines (19g140 and 19g140) each stabilized by different trimers of gp120, one from the HIV-1_{89.6} strain and the other from background B4 Florida, have been shown to mimic the native HIV-1 envelope. The two trimeric HIV-1 Env2 vaccines are codon optimized for enhanced expression and have been shown to efficiently form and correct trimers *in vitro*. The proteolytic cleavage site, at the gp120/gp41 junction of these trimeric HIV-1 Env2 vaccines, has been modified to prevent cleavage of the two subunits.

To compare the immunogenicity of soluble, stabilized trimeric forms of Eav to unstabilized sgp140 and sgp120 versions with three vaccination regimens.

antibodies, 2) on cell mediated responses.



E: Monoclonal antibody recognition of recombinant antigens

[illegible]

FIGURE 1. All constructs efficiently express *in-vitro* and both GNC4 and T7 stabilized versions of app140 form trimers after boiling and denaturing conditions (D). X-tensions of codon optimized DNA sequences is greatly enhanced compared to wild-type (C). Purified recombinant proteins used for proteinase K digestion are shown as recovered a panel of monoclonal antibodies (E).

Figure 2: Immune Response




FIGURE 2. BALB/c mice ($n=5$) were primed at day 0 with either 2 μ g DNA (D) by gene gun or inoculated 17 weeks later with recombinant protein (P), and subsequently boosted at weeks 4 and 8 as indicated. Sera, collected at week 10 were analyzed for anti-Eav specific antibodies. Similar titers of total IgG anti-Eav antibodies were observed in mice vaccinated with DNA expressing any of the envelope proteins, regardless of the regimen used to inoculate the mice. In addition, the total anti-Eav IgG antibody titers were similar in mice vaccinated with DNA or recombinant proteins.

Table 1: Antibody: Antigen Recognition				
Coating Antigen	DNP		BPP	
	(Test IgG Abs Titers 1X 10 ⁴)	(Test IgG Abs Titers 1X 10 ⁵)	(Test IgG Abs Titers 1X 10 ⁴)	(Test IgG Abs Titers 1X 10 ⁵)
gp120	0.78	0.12	0.09	0.03
gp140	0.77	0.58	0.28	0.26
gp120 (-FT)	0.77	0.51	0.29	0.29
gp140 (-FT)	0.77	0.51	0.29	0.29

Table 1. Ten week sera from mice vaccinated with $\text{gp140}_{\text{env}}/(\text{FTT})$, and $\text{gp140}_{\text{env}}/(\text{GNC})$ via DNA prime and either DNA (DND) or DADP as adjuvants. 3-6 fold higher Ab titres were obtained against $\text{gp140}_{\text{env}}$ or gp140_{env} (FTT) antigens than against gp120_{env} antigens. Mice vaccinated with $\text{gp140}_{\text{env}}$ or gp140_{env} (FTT) recombinant proteins (PPTT) had similar titres regardless of the antigen tested. Similarly, mice vaccinated with $\text{gp120}_{\text{env}}$ or $\text{gp120}_{\text{env}}$ (FTT) had similar Ab titres.

C3d as a molecular adjuvant

Previous work from our laboratory has shown:
 • 3 species of murine CDM (mCDM) fused to HIV-1 envelope and hemagglutinin (HA) of measles and influenza can act as a molecular adjuvant and enhance transmembrane and affinity maturation of antibodies.
 • HA-mCDM can afford protect against virus challenge with ten times less DNA than HA alone, and




Table 2: ELISpot

	# spots (hot cells) R-4			# spots (hot cells) NF-2		
	P1	P6	P15/16	P1	P6	P15/16
(-FT)	43	31	8	24	13	7
(-FT)Cl ₄	43	28	9	19	15	3
(-FT)Cl ₄	64	17	9	43	17	13
(-FT)Cl ₄	38	67	7	43	17	8

Table 3. Proliferation

14-deoxylinolenic incorporation CPM per 10 ⁶ cells		P1		P10		E10	
(47T)	379	599	-	273			
(47T) C ₂₄	1332	849	37	543			
(47T) C ₂₄	903	1005	-	1240			
(47T) C ₂₄	1137	1153	-	464			

Figure 3: Expression & Immunogenicity of Env-C3d





Figure 2. DNA vaccine plasmids encoding Env-C3d fusion were constructed and tested for cytotoxicity; even after the addition of C3d, gp140-gp127 trimers were stable (A). Mice were vaccinated as described in Figure 1B. (B) A7 model cell lines were infected with the virus and the amount of virus was determined by the amount of virus in the supernatant. At the same time, the amount of virus in the supernatant was determined by the amount of virus in the supernatant.



protein pool # 2

protein pool # 1

Mice (n=3), described in Figure 3 were given a 4th inoculation of DNA at week 28, and spleens were collected 10 days later. Spleenocytes were prepared and 1x10⁶ cell/ml were re-stimulated with peptide pools HIV-1 MN Env at 10 µg/ml or with 1 µg/ml recombinant protein. For ELISpot assays, spleenocytes were restimulated overnight and added to pre-coated plates (B&D Systems). Figures represent responses against the whole pool of HIV-1 MN recombinant to the entire env+gp120 mixture of Env in each of 16 reactions.

SUMMARY

- The results of this study show that codon-optimized DNA vaccines expressing various Eavs elicit similar, high levels of anti-Eav Abs, as protein inoculations.
- Codon-optimized sequences blunt the effects of C3d, in its ability to enhance the immunogenicity of Eav. However, C3d plays a role in enhancing a balanced T helper cell response.

ACKNOWLEDGEMENTS

ACKNOWLEDGMENTS

This research was supported by grant award AI-44325 and AI-51213 to T.M.R. from the National Institute of Allergy and Infectious Diseases. The authors thank Douglas Feron for supplying the murine C1d construct. HIV-Ig & HIV-1 MN peptides were obtained through the AIDS Research and Reference Reagent Program NIAID, NIH; HIV-Ig from NABI and NHI RI.